摘要:
A non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active pharmaceutical, therapeutics. The systems and methods described herein provide for the following: the ability to deliver macromolecule doses without injections; the ability to deliver cargo, such as (but not limited to) siRNA or antisense molecules into intracellular compartments where their activity is required; and the delivery of nanoparticles and dendrimer-based carriers across biological membranes, which otherwise would have been impeded due to the barrier properties of most such membranes.
摘要:
Methods of breaking down a biofilm or inhibiting, preventing or treating a microbial infection that produces a biofilm are disclosed, which involves administration of a polypeptide that has one or more HMG-box domains to a subject suffering from the infection or having the biofilm. By competing with microbial proteins that bind to DNA scaffold in the biofilm, these polypeptides destabilize the biofilm leading to destruction and removal of the biofilm by the immune system.
摘要:
The present invention relates to cephalosporin derivatives having β- lactamase inhibitory activity. The compounds are useful in preventing or treating bacterial resistance to an antibiotic, e.g. a β-lactam antibiotic. Disclosed herein are compounds that are inhibitors of class B metallo-β-lactamases, as well as class A, C, and D serine β-lactamases. In some preferred embodiments, the compounds are 3'- thiobenzoate derivatives of a cephalosporin. Pharmaceutical compositions, methods, uses, kits and commercial packages comprising the compounds are also disclosed.
摘要:
The disclosure relates to uses of a purified or isolated lectin to kill bacteria, viruses, and other pathogens. In certain embodiments, the disclosure relates to method of treating or preventing an infection comprising administering a purified or isolated galectin to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnosed with a pathogenic infection.
摘要:
Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.
摘要:
A presente invenção descreve novos compostos antifúngicos que são éteres aralquil benzílicos, da fórmula (I): onde: Ar representa aril, imidazolil, 1,2,4-triazolil, benzimidazolil; R 1 , R 2 , R 4 e R 5 representam, independentemente, hidrogênio, halogênio, C 1-6 alquil; R 3 representa halogênio, C 1-6 alquil ou O-R', onde R' representa hidrogênio ou alquilas inferiores; R 6 representa aril, aril substituído, trifluormetil, triclorometil ou O-R', onde R' representa hidrogênio ou alquilas inferiores, sendo os substituintes do aril um halogênio ou um radical tetrazolil; n e m representam, independentemente, um número inteiro compreendido entre 0 e 5; com a condição de que, quando Ar for imidazolil, R 3 for cloro, R 6 for p -fenila e R 1 , R 2 , R 4 e R 5 forem hidrogênios, n deve ser diferente de 2. Quando n e m for diferente de 0 e 1, R 3 ou R 6 podem ser representados por substituintes não necessariamente iguais A presente invenção também se refere aos seus sais, solvatos, pró-drogas, ésteres, enantiômeros e/ou diastereoisômeros farmaceuticamente aceitáveis, ou misturas dos mesmos, aos processos para a preparação dos referidos compostos, a compostos intermediários, a composições farmacêuticas compreendendo os referidos compostos e/ou derivados, aos medicamentos compreendendo os referidos compostos e/ou derivados, assim como aos usos e métodos dos referidos compostos e/ou derivados para o tratamento e/ou prevenção de condições e/ou doenças causadas por microorganismos, tais como, fungos, bactérias e/ou protozoários, para a inibição da proliferação e/ou sobrevivência dos ditos microorganismos, para tratamento e/ou prevenção de colonização de microrganismos em um indivíduo, e para a manufatura de um medicamento.
摘要:
The present invention provides therapeutic and prophylactic compositions for use in treating and preventing disorders involved epithelial cell apoptosis, such as gastrointestinal disorders (e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis) in a subject, such as a human patient.
摘要:
Provided are improved pharmaceutical compositions that comprise ligands or agonists to prostaglandin EP receptors, and/or cyclic AMP enhancers, and suitable organic solvents that are substantially free of methyl acetate, the compositions being provided for storage and/or use in an endotoxin-free vessel, such as a tube or PE bag. The compositions are suitable for in vitro, ex vivo, and in vivo use, and in particular for ex vivo therapeutic use, such as in hematopoietic stem cell transplants. Also provided are methods of using the compositions in ex vivo therapeutic applications, and methods of preparing the compositions. Kits with instructions on use are also provided.
摘要:
The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. The invention also provides method of making novel flavin derivatives.